Pharmacogenomics of Orofacial Pain Management (R01)

archived

The goal of this funding opportunity announcement (FOA) is to encourage research on the genetic basis of variability in therapeutic drug responses and adverse events in individuals with painful conditions of the dental, and orofacial region. The objectives are to determine the role of genetic variability in pharmacokinetics, pharmacodynamics, and drug toxicities that contribute to and predict the clinical outcomes of analgesic treatment of individuals with acute and chronic pain conditions. Delineation of genetic variation in drug and neurotransmitter metabolizing enzymes and transporters, drug target molecules such as enzymes and receptors, and associated post-receptor intracellular signaling pathway molecules is an important outcome of this FOA. Identification of key molecular signatures that are predictive of a therapeutic response is a second objective. Clinical and basic science researchers are encouraged to form multidisciplinary teams to effectively address the goals of this FOA. The ability to categorize individuals who differ in their responses to analgesic therapy will aid health care providers in their ability to prescribe the best treatments for acute and chronic pain patients with a personalized/ precision approach. Although this FOA is focused on orofacial pain, it also may serve as a catalyst for the pain research community to explore new pharmacogenomics studies in chronic pain conditions that overlap with temporomandibular joint disorder.

High